ZYMEWORKS INC.

ZYME ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Revenue $106.0M $76.3M $76.0M $412.5M $26.7M $39.0M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $143.6M $208.6M $199.8M $171.2M
SG&A Expense $61.5M $61.5M $70.4M $73.4M $42.6M $55.2M
Operating Income $-92.5M $-137.1M $-138.1M $130.5M $-215.6M $-187.5M
Operating Margin -87.3% -179.7% -181.6% 31.6% -808.2% -481.3%
Interest Expense
Pretax Income $-79.8M $-116.6M $-119.2M $135.2M $-212.4M $-180.1M
Income Tax Expense $1.4M $6.1M $-568.0K $10.9M $-516.0K $429.0K
Net Income $-81.1M $-122.7M $-118.7M $124.3M $-211.8M $-180.6M
Net Margin -76.6% -160.8% -156.1% 30.1% -794.0% -463.5%
EPS (Basic) $-1.08 $-1.62 $-1.72 $1.91 $-4.11 $-3.58
EPS (Diluted) $-1.08 $-1.62 $-1.72 $1.90 $-4.61 $-3.58
Shares Outstanding (Basic) 75.4M 75.8M 68.9M 65.2M 51.6M 50.4M
Shares Outstanding (Diluted) 75.4M 75.9M 68.9M 65.2M 52.1M 50.4M
Dividends Per Share